Targeting Gleevec resistance in CML patients: Tumor suppressor p53 suppressed miR-144/451 contributes to the gleevec sensitivity in CML, 7/November/2013, 7.03 am

Targeting Gleevec resistance in CML patients: Tumor suppressor p53 suppressed miR-144/451 contributes to the gleevec sensitivity in CML, 7/November/2013, 7.03 am https://genomediscovery.org/wp-content/themes/fildisi/images/empty/thumbnail.jpg 150 150 https://genomediscovery.org/wp-content/themes/fildisi/images/empty/thumbnail.jpg November 7, 2013 November 7, 2013

Idea Proposed by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To cite: Boominathan, Targeting Gleevec resistance in CML patients: Tumor suppressor p53 suppressed miR-144/451 contributes to the gleevec sensitivity in CML, 7/November/2013, 7.03 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org